Latest Nuclear Medicine News

Page 2 of 3
4DMedical has gained Canadian regulatory approval for its innovative CT – VQ™ ventilation-perfusion imaging technology, enabling immediate commercial rollout through Philips and expanding its North American footprint.
Ada Torres
Ada Torres
15 Dec 2025
4DMedical secures a key clinical adoption milestone as the University of Miami begins using its CT – VQ™ respiratory imaging technology, following Stanford’s lead. Meanwhile, Lahey Hospital inks a two-year deal for IQ-UIP™, underscoring growing traction in US academic medical centers.
Ada Torres
Ada Torres
10 Dec 2025
4DMedical has expanded its partnership with Philips, securing a US$10 million order commitment to distribute its CT – VQ™ lung imaging technology across North America, aiming to transform pulmonary diagnostics.
Ada Torres
Ada Torres
3 Dec 2025
Cyclopharm Limited reaffirms its ambitious target of 250–300 US Technegas installations by late 2026, driven by FDA approval, CMS reimbursement, and a growing pipeline of healthcare sites. The company reports record half-year revenue growth, signaling strong momentum in the expanding lung imaging market.
Ada Torres
Ada Torres
19 Nov 2025
4DMedical secures a major commercial breakthrough with Stanford University adopting its FDA-cleared CT, VQ™ technology, while its partnership with AstraZeneca rapidly scales lung screening across Brazil.
Ada Torres
Ada Torres
22 Oct 2025
4DMedical has won a crucial US Medicare reimbursement for its CT, VQ™ lung imaging software, paving the way for rapid adoption across American hospitals. This milestone follows FDA clearance and promises to transform lung diagnostics with safer, faster scans.
Ada Torres
Ada Torres
3 Sept 2025
4DMedical Limited has secured FDA clearance for CT – VQ™, the first non-contrast CT-based ventilation-perfusion imaging technology, promising to transform lung diagnostics by replacing traditional nuclear scans.
Ada Torres
Ada Torres
1 Sept 2025
Clarity Pharmaceuticals reported a $64.3 million loss for FY2025 alongside significant clinical progress and a $203.6 million placement to fund its radiopharmaceutical pipeline expansion.
Ada Torres
Ada Torres
28 Aug 2025
Cyclopharm Limited reports a 26% revenue jump to $15.42 million in H1 2025, driven by rapid U.S. expansion and extended patent protections for its Technegas® lung imaging technology.
Ada Torres
Ada Torres
27 Aug 2025
Integral Diagnostics posts robust FY25 results with strong revenue growth and merger synergies exceeding expectations, setting a confident tone for FY26.
Ada Torres
Ada Torres
26 Aug 2025
Clarity Pharmaceuticals has bolstered its cash reserves to approximately $288 million following a $203 million institutional placement, while reporting significant clinical progress across multiple copper-based radiopharmaceutical trials targeting prostate cancer and neuroendocrine tumours.
Ada Torres
Ada Torres
31 July 2025
Starpharma reports a 165% rise in FY25 customer receipts, advances its clinical-stage DEP® assets, and secures new distribution deals in Asia and Saudi Arabia.
Ada Torres
Ada Torres
31 July 2025